Drug Trial Radar · NCT04181827
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
419
Actual
Start
Jun 12, 2020
Primary completion
May 1, 2024
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
Conditions
- Multiple Myeloma
Interventions
Cilta-celDrug
Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).
PomalidomideDrug
Pomalidomide 4 mg will be administered orally.
BortezomibDrug
Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).
DexamethasoneDrug
Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.
DaratumumabDrug
Daratumumab 1800 mg will be administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)
Locations
88 sites in 16 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Cancer Center-Scottsdale
Phoenix, Arizona
Stanford University Medical Center
Stanford, California
Colorado Blood Cancer Institute
Denver, Colorado
Yale New Haven Hospital
New Haven, Connecticut
University Of Miami Leonard M Mille School Of Medicine SCCC
Miami, Florida
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas
Westwood, Kansas
University Of Maryland Medical Center
Baltimore, Maryland
Mayo Clinic - Rochester
Rochester, Minnesota
Washington University School Of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center
New York, New York
University of Rochester Medical Center
Rochester, New York
Duke University Medical Center
Durham, North Carolina
The Ohio State University
Columbus, Ohio
Huntsman Cancer Institute
Salt Lake City, Utah
Wisconsin Institutes for Medical Research
Madison, Wisconsin
Medical College Of Wisconsin
Milwaukee, Wisconsin
Royal Adelaide Hospital
Adelaide, Australia
Royal Prince Alfred Hospital
Camperdown, Australia
Royal Brisbane and Womens Hospital
Herston, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Alfred Health
Melbourne, Australia
Fiona Stanley Hospital
Murdoch, Australia
Universitair Ziekenhuis - Antwerpen
Antwerp, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, Belgium
Rigshospitalet
Copenhagen, Denmark
CHRU de Lille Hopital Claude Huriez
Lille, France
Hospices Civils de Lyon HCL
Lyon, France
CHU de Montpellier Hopital Saint Eloi
Montpellier, France
C.H.U. Hotel Dieu - France
Nantes, France
Hopital Saint Louis
Paris, France
CHU De Poitiers
Poitiers, France
Institut Universitaire du cancer de Toulouse-Oncopole
Toulouse, France
Universitaetsklinikum Koeln
Cologne, Germany
Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden
Dresden, Germany
Universitaetsklinikum Hamburg Eppendorf
Hamburg, Germany
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.